Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib Mesylate
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Myeloid, Chronic-Phase
Conditions
Leukemia, Myeloid, Chronic-Phase
Trial Timeline
Jul 1, 2009 → Jan 1, 2017
NCT ID
NCT01827930About Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib Mesylate
Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib Mesylate is a phase 3 stage product being developed by Novartis for Leukemia, Myeloid, Chronic-Phase. The current trial status is terminated. This product is registered under clinical trial identifier NCT01827930. Target conditions include Leukemia, Myeloid, Chronic-Phase.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01827930 | Phase 3 | Terminated |
Competing Products
20 competing products in Leukemia, Myeloid, Chronic-Phase